(NASDAQ: LEXX) Lexaria Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.15%.
Lexaria Bioscience's earnings in 2026 is -$7,732,026.On average, 4 Wall Street analysts forecast LEXX's earnings for 2026 to be -$9,228,364, with the lowest LEXX earnings forecast at -$11,174,178, and the highest LEXX earnings forecast at -$7,027,239. On average, 3 Wall Street analysts forecast LEXX's earnings for 2027 to be -$7,837,789, with the lowest LEXX earnings forecast at -$7,530,424, and the highest LEXX earnings forecast at -$8,068,312.
In 2028, LEXX is forecast to generate -$7,079,293 in earnings, with the lowest earnings forecast at -$6,801,674 and the highest earnings forecast at -$7,287,507.